Keywords: replagel, cleared, pediatric, fabry, disease, european, medicines

Replagel cleared for pediatric Fabry disease

Article | 30 October 2006

Print This

The European Medicines Agency (EMEA) has announced a licence variation for Replagel (agalsidase alfa) to include children with Fabry disease ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in